Breast Cancer Research Program
The Sarah Cannon Research Institute and Tennessee Oncology
Editorial Director, Hematology/Oncology
Senior Clinical Editor
Chief Innovation Officer
Senior Director, Oncology Programs and Partnership Development
This program is intended for physicians and other healthcare professionals who provide care for patients with metastatic breast cancer.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 15, 2013, through January 14, 2014:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Download these slides on treatment strategies for HER2+ EBC to review the most recent data on using trastuzumab/pertuzumab, T-DM1, and neratinib.
Expert commentary from CCO on choosing specific CDK4/6 inhibitors using differences in safety and patient presentation characteristics.
Download this CME-certified slideset with expert analysis on key studies in early and locally advanced/metastatic breast cancer from the 2018 SABCS annual meeting.
Read expert answers to audience questions on the use of PARP inhibitors for the treatment of breast cancer from a CCO symposium at SABCS 2018.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.